We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
The latest findings build on experiments from over a century ago
Brussels launches talks for mRNA jabs to augment existing contract with BioNTech/Pfizer
Addressing this IP issue is crucial to ensuring pharmaceutical products are available in future emergencies
Big-selling molnupiravir treatment produces permanent mutations that can be passed from patient to patient
London-listed group has signed 50% more clients for its complex cell and gene therapy since end of last year
I would like to gift my son some money following the death of my mother
Using AI should speed up detection of diseases caused by genetic variants but it does not guarantee success
First example of artificial intelligence helping to accelerate diagnosis of diseases caused by genetic variants
Experimentation continues on measures to tackle addiction and fatal overdoses
New rules are designed to make medicines cheaper for American seniors. But companies warn innovation will suffer
Jonathan Milner says deal materially undervalues Cambridge-based life sciences company
Climate change helps the spread of infectious diseases. Plus: rise in fungal infections highlights risks of antimicrobial resistance; Sydney shows how to almost eliminate HIV transmission; wait goes on for effective Long Covid treatments
Unlike the vaccine race, there is limited funding to treat a condition that is often debilitating
Despite progress on a flu jab, the biotech group will be lossmaking for the next three years
Trial finds latest version elicited better immune response than existing jabs
Drug regulator’s decision is the first step towards a new round of jabs as cases rise in the US
Danish pharma chief is leading the expansion of blockbuster obesity drug that propelled shares to record high
Inceptive’s Jakob Uszkoreit, a pioneer of the technology behind ChatGPT, attracts Nvidia funding to design ‘biological software’
Preliminary studies find exposure to prevalent XBB.1.5 strain elicits antibodies to BA.2.86
German pharmaceutical glassware company’s ebitda margin has risen from 23% in 2020 to 28% in first nine months of the year
Weight-loss medication can boost global welfare, but should not replace healthy habits
Biotech has been criticised for closing its $8bn acquisition of cancer test company Grail without regulatory approval
Shares rise after Danish pharma group launches anti-obesity drug Wegovy in UK
Private equity group’s bid for researcher comes as the biomedical market is slowing down post-Covid
Treatment whose rollout was delayed by pandemic will now be run by Swiss group Stallergenes Greer
International Edition
